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Guvenc Kockaya, MD
a
 and Albert I. Wertheimer, PhD
b 
a
Istanbul University, Istanbul Medicine Faculty, Pharmacology and Clinical Pharmacology Department 
b
Temple University, School of Pharmacy, Center for Pharmaceutical Health Services Research 
The purpose of this commentary is to (1) review the definition and potential benefits of translational science research, (2) comment 
on funding trends for translational science, (3) pose a question for scientists to discuss, and (4) propose recommendations for such a 
discussion. 
Definition and Potential Benefits of Translational 
Science/Research 
Translational science/research is a new and developing 
method for improving human health. The meaning of the 
method is translating scientific discoveries into practical 
applications. In the beginning, discoveries started at “the 
bench” with basic research — in which scientists study 
disease at a molecular or cellular level — then progress to the 
clinical level, or the patient's “bedside”. 
This bench-to-bedside approach can be a two way method. 
One way is from the basic scientist to clinical scientist. For 
example, basic scientists can find new bio-markers, new ways 
and new opportunities for clinicians to help patients. In the 
other direction, clinicians can provide data to basic scientists 
for developing new opportunities to investigate. 
Clinical research is complex and barriers can develop 
between clinical and basic research. Communication is not 
always linear or direct. However, such barriers between 
clinical and basic research can be overcome by the 
translational approach since basic and clinical researchers 
work more as a team and use iterative communication 
strategies while the research is being designed, conducted, 
and analyzed. We propose that the team model is more 
effective than a single direction approach and that 
translational science has become the new engine for 
developing methods for improving human health.  
Clinical and Translational Science Awards 
To help foster the translational science approach, the 
National Institutes of Health (NIH) held the Clinical and 
Translational Science Awards (CTSA) Consortium in October 
2006 for improving the new vision named translational 
science.
1 
The purpose of the CTSA Program, which the 
National Center for Research Resources (NCRR) is leading on 
behalf of the NIH Roadmap for Medical Research 
(http://www.ncrr.nih.gov/), is to assist institutions to forge a 
uniquely transformative, novel, and integrative academic 
home for Clinical and Translational Science that has the 
consolidated resources to captivate, advance, and nurture a 
cadre of well-trained multi- and inter-disciplinary 
investigators and research teams; create an incubator for 
innovative research tools and information technologies; and 
synergize multi-disciplinary and inter-disciplinary clinical and 
translational research and researchers to catalyze the 
application of new knowledge and techniques to clinical 
practice at the front lines of patient care.
1 
These efforts have resulted in many researchers who are 
using the translational method in their research.  Also the 
research budgets of institutes are being allocated to 
translational research projects and this allocation is 
continuing to grow. 
Cost-effectiveness of Translational Science/Research 
In light of this new paradigm, we need to ask: “Are 
translational findings useful and cost-effective for patients 
and society?” If such an approach is not cost-effective, these 
budgets will be wasted. On the other hand, if this approach is 
cost-effective, it would be wise to allocate additional budget 
amounts into translational science research projects. 
For example, if a biomarker for detecting kidney injury caused 
by diabetes or hypertension in an early phase could be 
identified, then treatment could be improved
2-5
. However, 
the question becomes: “Is the bio-marker affordable enough 
so that it would be cost-effective to screen most diabetes or 
hypertension patients?” 
In order to answer such a question, valid estimates related to 
prevalence and incidence of disease, treatment costs, 
screening costs, cost of illness, specificity of bio-markers, 
rates of inflation, and other factors must be developed. Such 
an approach would allow the consideration of potential cost-
savings through translational science. 
Recommendations for Future Discussion 
According to the U.S. Congressional Budget Office, there is “a 
limited amount of evidence available about which treatments 
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work best for which patients and whether the added benefits 
of more cost-effective but more-expensive services are 
sufficient to warrant their added costs. Together, those 
findings suggest that generating better information about the 
costs and benefits of different treatment options – through 
research on the comparative effectiveness of those options – 
could help reduce health care spending without adversely 
affecting overall health.”
6 
We recommend that comparative effectiveness analysis 
should be integrated into translational science and research 
before, during, and after such “bench-to-bedside” research is 
conducted. We propose an enhanced approach that could be 
referred to as “bench-to-beside-to-best practices” research. 
This approach would incorporate basic, clinical, and cost-
effectiveness research in an iterative manner so that analysis 
could be conducted before budgets grow out of control.  
We propose several questions and ideas for further 
discussion in this area: 
1. Should NIH expand its support for new projects focused 
on performing cost-effectiveness analysis of translational 
science?
7
 
2. Should translational science researchers show the impact 
of a new translational trial with estimated cost-
effectiveness or cost-utility figures before getting 
permission for budget or ethics committee work?
8
 
3. Should NIH assign priority for new translational trials? 
For example; cardiovascular diseases are the most 
common ailments and at the top of the burden of illness 
estimates. Should translational research for 
cardiovascular diseases be given a higher priority rather 
than other diseases based upon potential cost-
effectiveness impact? 
4. Translational science/research may help reduce the 
budgets of drug development. Should pharmaceutical 
firms contribute more to the budgets of translational 
science/research?
9
 
5. Translational science/research may help reduce the 
budgets of health insurers. Should health insurers 
contribute more to the budgets of translational 
science/research? 
6. Should comparative effectiveness be a required part of 
the drug approval process? 
7. Should comparative effectiveness be a required part of 
the drug formulary decision process? 
8. Should government funding support post-graduate 
programs for training individuals in the conduct of 
translational science/research trials and comparative 
effectiveness analysis?     
We present these ideas for further discussion.  New ideas 
could be added and some ideas could be ignored. 
However, science and reality won`t wait. We need to talk 
about the cost-effectiveness of translational science and 
how the comparative effectiveness of new treatment 
modalities affect budgets.  
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